ViaNautis Bio welcomed SCI Ventures as new investor, expanding CNS portfolio into spinal cord injury ViaNautis Bio, the biotech developing polyNaut® for precise, non‑viral delivery of genetic medicines, announced that SCI Ventures, a specialist venture fund backed by leading clinical centres and research foundations worldwide focused on advancing treatments and cures for paralysis, has joined the […]
AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s disease AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company developing targeted therapeutics for neurodegenerative diseases, announced that it has received Fast Track designation and clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug […]
Sofinnova Partners announced Myricx Bio agrees to be acquired by Novartis Sofinnova Partners, a leading European life sciences venture capital firm, announced that its portfolio company Myricx Bio has reached an agreement to be acquired by Novartis for up to $1.5 billion, including $1.1 billion cash upfront plus potential milestone payments. Sofinnova Partners seeded the […]
The heatwave has been replaced by heavy showers, but June is looking bright for our clients, with huge congratulations to Ona Therapeutics for its $86.6M Series B financing and to DaltonTx for the launch of its AI-enabled drug discovery platform. Dr. Hans Eriksson is joining FundaMental Pharma’s team as CMO and Renée Aguiar-Lucander participated in […]
Lund, Sweden, June 2, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York, at 8:45 AM EDT on Thursday, June 4, 2026. Read more…
